Skip to main content

Table 4 In vivo pharmacodynamic parameters of generic and innovator products of oxacillin by nonlinear regression from 4 independent experiments.

From: In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin

OXACILLIN (OXA) PRODUCTS Emax(log10CFU/g) SEM N SEM ED50(mg/kg) SEM BD (mg/kg) SEM 1 LKD (mg/kg) SEM Adj. R2 Sy|x P (CFA)
OXA-BMS (innovator) 5.42 0.08 1.73 0.13 45.19 2.32 62.24 3.07 108.36 7.32 0.99 0.23 NA
OXA-BLA 3.38 0.10 3.29 0.79 19.38 2.65 >750.00 - >750.00 - 0.98 0.21 <0.0001
OXA-CAR 3.69 0.10 1.81 0.20 25.44 2.20 97.61 16.13 >750.00 - 0.99 0.17 <0.0001
OXA-COL 3.14 0.12 1.93 0.36 35.41 3.71 132.29 33.04 >750.00 - 0.98 0.20 <0.0001
OXA-MEM 3.51 0.12 2.09 0.32 23.07 2.65 >750.00 - >750.00 - 0.96 0.32 <0.0001
OXA-OPH 3.11 0.15 NS - NS - >750.00 - >750.00 - 0.96 0.31 <0.0001*
OXA-QIM 2.22 0.10 2.72 0.60 25.00 3.95 >750.00 - >750.00 - 0.96 0.20 <0.0001
OXA-SCA 3.66 0.17 2.03 0.46 19.31 3.02 >750.00 - >750.00 - 0.95 0.31 <0.0001
OXA-SER - - - - - - - - - - - - NA
OXA-VIT 3.01 0.12 1.55 0.26 18.51 2.50 >750.00 - >750.00 - 0.97 0.20 <0.0001
  1. Abbreviators: Emax: maximum effect; N: Hill's slope; ED50: effective dose to reach 50% of Emax; BD: bacteriostatic dose; 1LKD: 1 log kill dose; Adj. R2: adjusted coefficient of determination; Sy|x: standard error of the estimate; SEM: standard error of the mean; NA: not applicable; Bold numbers: not statistically different from zero, invalid parameter. * CFA comparison of Emax only. † Pharmacodynamic profile fits to Gaussian instead of Hill's model.